Related Experiment Video
Updated: Apr 27, 2026
09:24
3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
Published on: September 13, 2018
8.4K
Landmarks in non-muscle-invasive bladder cancer
Laura S Mertens1, Yann Neuzillet2, Simon Horenblas1
1Department of Urology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.
Nature Reviews. Urology
|July 2, 2014
Summary
Non-muscle-invasive bladder cancer (NMIBC) is common and recurs frequently but has low mortality. Continued research is vital to improve bladder cancer outcomes despite diagnostic and therapeutic advancements.
Area of Science:
- Uro-oncology
- Cancer Research
Background:
- Bladder cancer comprises non-muscle-invasive (NMIBC) and muscle-invasive subtypes.
- NMIBC accounts for 75% of initial diagnoses, presenting high recurrence rates and low mortality risk.
- Despite historical advancements in detection, diagnosis, and treatment, bladder cancer remains heterogeneous.
Approach:
- Review of historical progress in bladder cancer management.
- Analysis of disease heterogeneity in pathology and molecular background.
- Identification of areas for future research to improve patient outcomes.
Key Points:
- NMIBC is the predominant form of bladder cancer diagnosis.
- Bladder cancer exhibits significant heterogeneity impacting treatment strategies.
- Progress in detection, diagnosis, and treatment has been substantial but requires further enhancement.
Conclusions:
- Ongoing research is essential to further improve outcomes for bladder cancer patients.
- Addressing the heterogeneity of bladder cancer is key to advancing patient care.
- Future efforts should focus on refining diagnostic and therapeutic approaches for bladder cancer.
